February 2020

Study Results Link Postpartum Depression to Inflammation

February 25, 2020

Pharmacy Times

The results of a recent study published in Brain, Behavior, and Immunity suggest that inflammation and the kynurenine pathway may be connected to postpartum depression (PPD) and therefore may present new treatment targets in severe PPD.

Clinical Evidence Exists for Allopregnanolone-based Treatments

February 24, 2020

Pharmacy Times

With the recent approval of a Zulresso, an allopregnanolone-based treatment for postpartum depression (PPD), many pharmacists and physicians have been researching the mechanisms and other information about the drug.

Brexanolone Demonstrates More Change from Baseline Compared with SSRIs

February 19, 2020

Pharmacy Times

The results of a systematic literature review published in CNS Drugs suggested that brexanolone injection, the first therapy approved by the FDA for the treatment of postpartum depression, is more effective than selective serotonin reuptake inhibitors in the treatment of women suffering from postpartum depression.